Amgen マネジメント
マネジメント 基準チェック /34
Amgenの CEO はBob Bradwayで、 May2010年に任命され、 の在任期間は 14.5年です。 の年間総報酬は$ 22.64Mで、 7.9%給与と92.1%のボーナス（会社の株式とオプションを含む）で構成されています。 は、会社の株式の0.12%を直接所有しており、その価値は$ 175.94M 。経営陣と取締役会の平均在任期間はそれぞれ4.8年と7.9年です。
主要情報
Bob Bradway
最高経営責任者
US$22.6m
報酬総額
| CEO給与比率 | 7.9% |
| CEO在任期間 | 14.5yrs |
| CEOの所有権 | 0.1% |
| 経営陣の平均在職期間 | 4.8yrs |
| 取締役会の平均在任期間 | 7.9yrs |
経営陣の近況
Recent updates
Amgen Sells Off: Keep Calm And Buy The Dip
Nov 18Amgen's (NASDAQ:AMGN) Problems Go Beyond Weak Profit
Nov 08
Amgen: A Biotech Giant Offering Value And Growth In A Frothy Market
Nov 03Amgen Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Nov 02Amgen Q3 Earnings Review: So Many Questions, But MariTide Data Top Of The List
Oct 25Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Sep 26Amgen: Growth Is Still A Better Choice
Aug 28Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13CEO報酬分析
| 日付 | 総報酬 | 給与 | 会社業績 |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$4b |
| Jun 30 2024 | n/a | n/a | US$3b |
| Mar 31 2024 | n/a | n/a | US$4b |
| Dec 31 2023 | US$23m | US$2m | US$7b |
| Sep 30 2023 | n/a | n/a | US$8b |
| Jun 30 2023 | n/a | n/a | US$8b |
| Mar 31 2023 | n/a | n/a | US$8b |
| Dec 31 2022 | US$21m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$7b |
| Jun 30 2022 | n/a | n/a | US$7b |
| Mar 31 2022 | n/a | n/a | US$6b |
| Dec 31 2021 | US$22m | US$2m | US$6b |
| Sep 30 2021 | n/a | n/a | US$6b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$7b |
| Dec 31 2020 | US$20m | US$2m | US$7b |
| Sep 30 2020 | n/a | n/a | US$7b |
| Jun 30 2020 | n/a | n/a | US$7b |
| Mar 31 2020 | n/a | n/a | US$8b |
| Dec 31 2019 | US$20m | US$2m | US$8b |
| Sep 30 2019 | n/a | n/a | US$8b |
| Jun 30 2019 | n/a | n/a | US$8b |
| Mar 31 2019 | n/a | n/a | US$8b |
| Dec 31 2018 | US$19m | US$2m | US$8b |
| Sep 30 2018 | n/a | n/a | US$2b |
| Jun 30 2018 | n/a | n/a | US$2b |
| Mar 31 2018 | n/a | n/a | US$2b |
| Dec 31 2017 | US$17m | US$2m | US$2b |
報酬と市場: Bobの 総報酬 ($USD 22.64M ) は、 US市場 ($USD 12.73M ) の同規模の企業の平均を上回っています。
報酬と収益: Bobの報酬は、過去 1 年間の会社の業績と一致しています。
CEO（最高経営責任者
Bob Bradway (61 yo)
14.5yrs
在職期間
US$22,643,650
報酬
Mr. Robert A. Bradway, also known as Bob, has been the Chief Executive Officer of Amgen Inc. since May 23, 2012 and has been its President since May 2010. Mr. Bradway is responsible for the Amgen's global...
リーダーシップ・チーム
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 14.5yrs | US$22.64m | 0.12% $ 175.9m | |
| Executive VP & CFO | 4.8yrs | US$7.57m | 0.0046% $ 6.9m | |
| Executive Vice President of Operations | 8.3yrs | US$7.21m | 0.011% $ 17.2m | |
| Executive VP & CTO | less than a year | US$7.90m | 0.0094% $ 14.1m | |
| Executive Vice President of Global Commercial Operations | 6.2yrs | US$8.24m | 0.0075% $ 11.2m | |
| Chief Accounting Officer & VP of Finance | 1.3yrs | データなし | 0.00062% $ 933.0k | |
| Executive VP of Research & Development and Chief Scientific Officer | less than a year | データなし | データなし | |
| Vice President of Investor Relations | no data | データなし | データなし | |
| Executive VP | 9.3yrs | US$7.24m | 0.0046% $ 7.0m | |
| Senior VP of Worldwide Compliance & Business Ethics and Chief Compliance Officer | 4.8yrs | データなし | 0.0013% $ 2.0m | |
| Senior Vice President of Global Marketing & Access | less than a year | データなし | データなし | |
| Senior Vice President of Human Resources | 2.8yrs | データなし | 0.0012% $ 1.7m |
4.8yrs
平均在職期間
56.5yo
平均年齢
経験豊富な経営陣: AMGNの経営陣は 経験豊富 であると考えられます ( 4.8年の平均在職年数)。
取締役
| 名称 | ポジション | 在職期間 | 報酬 | 所有権 |
|---|---|---|---|---|
| Chairman | 13.1yrs | US$22.64m | 0.12% $ 175.9m | |
| Lead Independent Director | 11.9yrs | US$419.92k | 0.0013% $ 2.0m | |
| Co-Chair of Scientific Advisory Board | no data | US$292.01k | データなし | |
| Co-Chair of the Scientific Advisory Board | no data | データなし | データなし | |
| Independent Director | 4.3yrs | US$359.92k | 0.000080% $ 120.4k | |
| Independent Director | 7.8yrs | US$369.92k | 0.00023% $ 346.1k | |
| Independent Director | 11.1yrs | US$379.92k | 0.0023% $ 3.5m | |
| Independent Director | 8.1yrs | US$360.29k | 0.000080% $ 120.4k | |
| Independent Director | 6.5yrs | US$359.92k | 0.00015% $ 225.7k | |
| Independent Director | 12.5yrs | US$339.92k | 0.00051% $ 767.5k | |
| Independent Director | 6.9yrs | US$359.92k | 0.0012% $ 1.8m | |
| Independent Director | 3.3yrs | US$366.47k | 0.00017% $ 255.8k |
7.9yrs
平均在職期間
68yo
平均年齢
経験豊富なボード: AMGNの 取締役会 は 経験豊富 であると考えられます ( 7.9年の平均在任期間)。